MCID: ADN012
MIFTS: 45

Adenocarcinoma in Situ malady

Category: Cancer diseases

Aliases & Classifications for Adenocarcinoma in Situ

About this section

Aliases & Descriptions for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 11 39 13 68

Classifications:



External Ids:

Disease Ontology11 DOID:4943
MeSH39 D065311
SNOMED-CT62 51642000
NCIt45 C4123

Summaries for Adenocarcinoma in Situ

About this section
MalaCards based summary: Adenocarcinoma in Situ is related to large cell neuroendocrine carcinoma and fallopian tube adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways are Thyroid cancer and ID signaling pathway. Affiliated tissues include cervix, lung and testes, and related mouse phenotypes are pigmentation and cardiovascular system.

Related Diseases for Adenocarcinoma in Situ

About this section

Diseases in the Adenocarcinoma family:

adenocarcinoma in situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 109)
idRelated DiseaseScoreTop Affiliating Genes
1large cell neuroendocrine carcinoma29.6CDX2, KRAS, KRT20
2fallopian tube adenocarcinoma29.2CDKN1A, CDKN2A, CDX2, KRT20
3in situ pulmonary adenocarcinoma11.0
4adenocarcinoma10.7
5cervicitis10.4
6cervical adenocarcinoma10.3
7endocervicitis10.3
8peritoneal benign neoplasm10.3CDX2, KRT20
9dystonia10.3CDX2, KRT20
10anal canal paget's disease10.3CDX2, KRT20
11uterine ligament mucinous adenocarcinoma10.3CDX2, KRAS
12agenesis and aplasia of uterine body10.3KRAS, KRT20
13clitoris cancer10.3CDX2, KRT20
14ureter adenocarcinoma10.2CDX2, KRAS
15kimura disease10.2PAX2, PAX8
16extramedullary plasmacytoma10.2CDX2, KRT20
17connective tissue disease10.2PAX2, PAX8
18ovarian primitive germ cell tumor10.2PAX2, PAX8
19testicular malignant germ cell cancer10.2CDKN2A, WT1
20gastrointestinal neuroendocrine tumor10.2PAX2, PAX8
21cervix endometriosis10.2CDX2, KRT20
22bladder adenocarcinoma10.2CDKN2A, PAX2
23breast ductal carcinoma10.2KRAS, WT1
24postpoliomyelitis syndrome10.2CDKN2A, CDX2, KRAS
25aicardi-goutieres syndrome10.2CDKN2A, CDX2, KRAS
26subareolar duct papillomatosis10.2CDKN2A, PAX8
27pelvic inflammatory disease10.2CDX2, KRAS, KRT20
28anemia of prematurity10.2CDX2, KRAS, KRT20
29superficial urinary bladder cancer10.2PAX2, PAX8
30apocrine adenocarcinoma10.2CDX2, KRT20
31giant cell tumor10.2CDX2, KRAS, KRT20
32mucinous adenofibroma10.2PAX2, WT1
33papillary adenofibroma10.2CDX2, KRAS, KRT20
34sagittal sinus thrombosis10.2CDX2, KRAS, KRT20
35myotonia congenita10.2CDKN2A, CDX2, KRT20
36tabes dorsalis10.2CDX2, KRAS, KRT20
37neuroretinitis10.2CDX2, KRAS, KRT20
38mucosal melanoma10.2CDX2, KRT20
39colon signet ring adenocarcinoma10.2KRT20, PAX2
40pacinian tumor10.2CDKN2A, CDX2, KRT20
41exotropia10.2PAX8, WT1
42oral squamous cell carcinoma10.2CDX2, KRAS, KRT20
43pulmonary fibrosis and/or bone marrow failure, telomere-related, 110.2CDKN2A, KRAS, KRT20
44neuroendocrine tumor10.2CDX2, KRT20
45gastroesophageal junction adenocarcinoma10.2CDX2, KRAS, KRT20
46peripheral nervous system ganglioneuroblastoma10.2CDX2, WT1
47paraphimosis10.2CDKN2A, KRT20
48avian influenza10.2CDKN2A, WT1
49benign shuddering attacks10.2CDKN2A, KRAS, PAX8
50non-distal monosomy 10q10.1CDKN2A, KRAS, PAX8

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to adenocarcinoma in situ

Symptoms & Phenotypes for Adenocarcinoma in Situ

About this section

MGI Mouse Phenotypes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.5CDKN2A, KRAS, MCM2, PAX2
2MP:00053858.7CDKN1A, CDKN2A, CDX2, KRAS, PAX2, PAX8
3MP:00020068.5CDKN1A, CDKN2A, CDX2, KRAS, MCM2, WT1
4MP:00053847.8CDKN1A, CDKN2A, CDX2, KRAS, MCM2, PAX2
5MP:00053807.8CDKN1A, CDKN2A, CDX2, KRAS, MCM2, PAX2
6MP:00053897.8CDKN1A, CDKN2A, CDX2, KRAS, PAX2, PAX8
7MP:00053797.8CDKN1A, CDKN2A, CDX2, KRAS, MCM2, PAX2
8MP:00107687.4CDKN1A, CDKN2A, CDX2, CLDN1, KRAS, MCM2

Drugs & Therapeutics for Adenocarcinoma in Situ

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Cervarix16 44 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
FDA Label: -
Disease/s that Drug Treats:prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18
Indications and Usage:16 -
DrugBank Targets: -
Mechanism of Action:16 
Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins
Action: activates/ provokes production
FDA: -
2
Gardasil16 44 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
FDA Label: Gardasil
Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:16 GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets: -
Mechanism of Action:16 
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 206)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1VaccinesPhase 4, Phase 3, Phase 2, Phase 16611
2
TamoxifenapprovedPhase 3, Phase 239010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
3
Trastuzumabapproved, investigationalPhase 3, Phase 2784180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
4
Capecitabineapproved, investigationalPhase 3, Phase 21342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
5
Oxaliplatinapproved, investigationalPhase 3, Phase 2, Phase 1146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
6
LevoleucovorinapprovedPhase 2, Phase 3, Phase 172868538-85-2
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
 
(S)-Leucovorin
Citrovorum factor
L-Folinic acid
Levofolene
Levofolinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
7
Bevacizumabapproved, investigationalPhase 2, Phase 32020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
8
EpirubicinapprovedPhase 3, Phase 239456420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
9
FluorouracilapprovedPhase 3, Phase 2, Phase 1185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
10
Anastrozoleapproved, investigationalPhase 3, Phase 1, Phase 2279120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole
11
Fentanylapproved, illicit, investigational, vet_approvedPhase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
12
CetuximabapprovedPhase 2, Phase 3, Phase 1752205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
13
Letrozoleapproved, investigationalPhase 3, Phase 2, Phase 1397112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
 
D00964
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
14
Irinotecanapproved, investigationalPhase 2, Phase 3, Phase 1112397682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
15
Oxybutyninapproved, investigationalPhase 3685633-20-54634
Synonyms:
1508-65-2 (hydrochloride)
4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester
4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate
4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate
4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate
4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
4-Diethylamino-2-butinyl alpha-cyclohexylmandelat
4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate
5633-20-5
AC-2153
AC1L1ILV
BPBio1_000214
BRD-A65013509-003-03-8
BSPBio_000194
Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester
C07360
CCRIS 1923
CHEBI:7856
CHEMBL1231
CID4634
Cyclohexaneglycolic acid, .alpha.-phenyl-, 4-(diethylamino)-2-butynyl ester
Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester
Cystrin
D00465
DB01062
Ditropan
Ditropan, Lyrinel XL, Oxytrol, Oxybutynin
FT-0082890
HSDB 3270
I06-2117
L000923
LS-28714
 
Lopac0_000923
MolPort-003-849-741
NCGC00015767-06
NCGC00089795-02
Oxibutinina
Oxibutinina [INN-Spanish]
Oxibutyninum
Oxybutinin
Oxybutynin
Oxybutynin (USAN/INN)
Oxybutynin Base
Oxybutynin Chloride
Oxybutynin Hydrochloride
Oxybutynin [USAN:INN:BAN]
Oxybutynin topical gel
Oxybutynine
Oxybutynine [INN-French]
Oxybutyninum
Oxybutyninum [INN-Latin]
Oxytrol
Oxytrol (TN)
Pollakisu
Prestwick0_000287
Prestwick1_000287
Prestwick2_000287
Prestwick3_000287
S1754_Selleck
SPBio_002413
Transdermal patch
UNII-K9P6MC7092
oxybutynin
oxybutynin topical gel
transdermal patch
16
Exemestaneapproved, investigationalPhase 3218107868-30-460198
Synonyms:
(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
107868-30-4
6-Methylenandrosta-1,4-diene-3,17-dione
6-Methyleneandrosta-1,4-diene-3,17-dione
6-methylideneandrosta-1,4-diene-3,17-dione
AC-2171
AC1L1SRB
AC1Q6AAZ
Ambap107868-30-4
Aromasil
Aromasin
Aromasin (TN)
Aromasin, Exemestane
Aromasine
C056516
C08162
CHEBI:4953
CHEMBL1200374
CID60198
CPD000466314
Curator_000009
D00963
DB00990
EXE
EXEMESTANE
 
Exemestance
Exemestane
Exemestane (JAN/USP/INN)
Exemestane [USAN:INN:BAN]
Exemestano
Exemestano [INN-Spanish]
Exemestanum
Exemestanum [INN-Latin]
FCE-24304
Fce 24304
HMS2051J04
HSDB 7463
LS-19329
MLS000759419
MLS001424062
MolPort-003-847-343
NSC713563
Nikidess
PNU-155971
Pfizer brand of exemestane
S1196_Selleck
S1196_Sellek
SAM001246574
SMR000466314
UNII-NY22HMQ4BX
ZINC03973334
exemestane
17
MetforminapprovedPhase 3, Phase 21803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
18
leucovorinapproved, NutraceuticalPhase 2, Phase 3, Phase 1323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
19Angiogenesis InhibitorsPhase 2, Phase 34257
20Angiogenesis Modulating AgentsPhase 2, Phase 34185
21Anti-Bacterial AgentsPhase 3, Phase 211226
22Immunosuppressive AgentsPhase 3, Phase 2, Phase 113086
23Antibiotics, AntitubercularPhase 3, Phase 27180
24Interferon-alphaPhase 31152
25Antineoplastic Agents, PhytogenicPhase 2, Phase 3, Phase 15602
26Protective AgentsPhase 2, Phase 3, Phase 17443
27Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 17361
28Liver ExtractsPhase 3, Phase 2, Phase 14067
29Calcium, DietaryPhase 2, Phase 3, Phase 15713
30Alkylating AgentsPhase 3, Phase 2, Phase 14827
31Adjuvants, ImmunologicPhase 32554
32AntidotesPhase 2, Phase 3, Phase 11071
33Bone Density Conservation AgentsPhase 3, Phase 1, Phase 23376
34BCG VaccinePhase 3108
35Topoisomerase InhibitorsPhase 3, Phase 2, Phase 15069
36Estrogen AntagonistsPhase 3, Phase 2, Phase 11349
37MitomycinsPhase 3240
38Nucleic Acid Synthesis InhibitorsPhase 3, Phase 24962
39Antineoplastic Agents, HormonalPhase 3, Phase 2, Phase 15592
40Pharmaceutical SolutionsPhase 3, Phase 28192
41AntimetabolitesPhase 3, Phase 2, Phase 112054
42Estrogen Receptor ModulatorsPhase 3, Phase 2645
43Antiviral AgentsPhase 3, Phase 1, Phase 29967
44EstrogensPhase 3, Phase 2, Phase 12542
45Anti-Infective AgentsPhase 3, Phase 1, Phase 222062
46interferonsPhase 3, Phase 1, Phase 22175
47Selective Estrogen Receptor ModulatorsPhase 3, Phase 2601
48Hormone AntagonistsPhase 3, Phase 2, Phase 1, Early Phase 113180
49HormonesPhase 3, Phase 2, Phase 1, Early Phase 114415
50Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 2, Phase 1, Early Phase 113168

Interventional clinical trials:

(show top 50)    (show all 179)
idNameStatusNCT IDPhase
1V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)CompletedNCT01544478Phase 4
2Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®CompletedNCT01448447Phase 4
3Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast CancerCompletedNCT00742222Phase 4
4Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV VaccinesNot yet recruitingNCT03180034Phase 4
5Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO)Unknown statusNCT01429649Phase 3
6Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder CancerUnknown statusNCT01094964Phase 3
7Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)CompletedNCT00092521Phase 3
8Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy ParticipantsCompletedNCT00128661Phase 3
9Efficiency of Two Dimensional High Definition Versus Three Dimensional Endoscopic Systems in Transanal Endoscopic SurgeryCompletedNCT01498354Phase 3
10Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation TherapyCompletedNCT00053898Phase 3
11Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast CancerCompletedNCT01112254Phase 3
12Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by SurgeryCompletedNCT00647530Phase 3
13Intraoperative Gamma Camera for Breast Cancer SurgeryCompletedNCT00757302Phase 3
14Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal CancerCompletedNCT00975897Phase 2, Phase 3
15Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
16Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast CancerRecruitingNCT01905046Phase 3
17Oxybutynin Chloride in Managing Hot FlashesRecruitingNCT02961790Phase 3
18Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerRecruitingNCT01272037Phase 3
19Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing CoordinatorActive, not recruitingNCT00321048Phase 3
20Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone LumpectomyActive, not recruitingNCT00769379Phase 3
21Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the BreastActive, not recruitingNCT00470236Phase 3
22Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With MicroinvasionNot yet recruitingNCT02011997Phase 3
23Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)Unknown statusNCT00669747Phase 2
24C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal CancerUnknown statusNCT02344810Phase 1, Phase 2
25"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"Unknown statusNCT01641406Phase 2
26Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer SurvivorsUnknown statusNCT02150525Phase 2
271st-line Activity of Dovitinib and Correlation With Genetic Changes in RCCUnknown statusNCT01791387Phase 2
28Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)CompletedNCT00365716Phase 2
29Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast CancerCompletedNCT00054301Phase 2
30Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal CancerCompletedNCT00281736Phase 2
31Phase II Study of Irinotecan and PanitumumabCompletedNCT00836277Phase 2
32Endoscopic Therapy of Early Cancer in Barretts EsophagusCompletedNCT00217087Phase 2
33Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)CompletedNCT01023477Phase 1, Phase 2
34Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal CancerCompletedNCT00551421Phase 1, Phase 2
354-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in SituCompletedNCT00952731Phase 2
36MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-SituCompletedNCT00586326Phase 2
37Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast CancerCompletedNCT00416403Phase 2
38Breast Cancer Chemoprevention by SOM230, an IGF-I Action InhibitorCompletedNCT01372618Phase 2
39Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the BreastCompletedNCT03002766Phase 2
40Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal CancerCompletedNCT00655499Phase 2
41Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney TumorsCompletedNCT00335556Phase 2
42Use of N-Acetylcysteine During Liver ProcurementCompletedNCT01394497Phase 2
43Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal SymptomsCompletedNCT01194440Phase 2
44Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal CancerRecruitingNCT03053544Phase 2
45Study of a Recombinant Adenovirus to Treat Localized Prostate CancerRecruitingNCT01931046Phase 1, Phase 2
46Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving SurgeryRecruitingNCT02617082Phase 2
47Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing SurgeryRecruitingNCT02694809Phase 2
48A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible CancersRecruitingNCT02643303Phase 1, Phase 2
49Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)RecruitingNCT02730923Phase 1, Phase 2
50Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast CancerRecruitingNCT02636582Phase 2

Search NIH Clinical Center for Adenocarcinoma in Situ


Cochrane evidence based reviews: adenocarcinoma in situ

Genetic Tests for Adenocarcinoma in Situ

About this section

Anatomical Context for Adenocarcinoma in Situ

About this section

MalaCards organs/tissues related to Adenocarcinoma in Situ:

36
Cervix, Lung, Testes, Lymph node, Colon, Ovary, Appendix

Publications for Adenocarcinoma in Situ

About this section

Articles related to Adenocarcinoma in Situ:

(show top 50)    (show all 253)
idTitleAuthorsYear
1
Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies. (27565930)
2016
2
Diagnosis of lung adenocarcinoma in situ and minimally invasive adenocarcinoma from intraoperative frozen sections: an analysis of 136 cases. (27174927)
2016
3
Risk of persistent and recurrent cervical neoplasia following incidentally detected adenocarcinoma in situ. (27908632)
2016
4
Gastric-type adenocarcinoma in situ of uterine cervix: cytological and histopathological features of two cases. (27334141)
2016
5
Syringocystadenocarcinoma Papilliferum In Situ, a Variant of Cutaneous Adenocarcinoma In Situ: A Case Report With Literature Review. (27533073)
2016
6
Thin-section computed tomography-histopathologic comparisons of pulmonary focal interstitial fibrosis, atypical adenomatous hyperplasia, adenocarcinoma in situ, and minimally invasive adenocarcinoma with pure ground-glass opacity. (27666606)
2016
7
Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung. (27597281)
2016
8
Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma-analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules. (27067781)
2016
9
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. (27137345)
2016
10
Case of anal adenocarcinoma in situ with pagetoid spread but without macroscopic abnormality in anal mucosa. (27666572)
2016
11
Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists. (27174588)
2016
12
The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. (25956340)
2015
13
Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. (25987897)
2015
14
Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard? (25769659)
2015
15
Endocervical adenocarcinoma in situ presenting in fundal endometrial polyp: the mother of all skip lesions. (25844546)
2015
16
Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation. (25970685)
2015
17
Secondhand Tobacco Smoke Exposure and Lung Adenocarcinoma In Situ/Minimally Invasive Adenocarcinoma (AIS/MIA). (26503035)
2015
18
Conservative Treatment Seems the Best Choice in Adenocarcinoma In Situ of the Cervix Uteri. (25943864)
2015
19
Cytological variations and typical diagnostic features of endocervical adenocarcinoma in situ: A retrospective study of 74 cases. (25972909)
2015
20
Prognosis and status of lymph node involvement in patients with adenocarcinoma in situ and minimally invasive adenocarcinoma-a systematic literature review and pooled-data analysis. (26716039)
2015
21
Coexistence of mature cystic teratoma and adenocarcinoma in situ within atypical proliferative mucinous tumour of ovary--a case report of 35-year-old woman. (26050362)
2015
22
Cytological Diagnoses of Adenocarcinoma in situ of the Cervix: Common Misdiagnoses. (25766846)
2015
23
Laparoscopic Oophorectomy and Radical Lymph Node Dissection for a Recurrent Adenocarcinoma In Situ of the Cervix. (27678792)
2015
24
Extrafascial Hysterectomy Without Preoperative Conization is Unacceptable in Patients With Adenocarcinoma in Situ Diagnosed by Cervical Punch Biopsy or Endocervical Curettage. (27679125)
2015
25
Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4A years after sublobar resection for adenocarcinoma in situ: report of a case. (25377270)
2014
26
Papillary adenocarcinoma in situ of the skin: report of four cases. (24855569)
2014
27
Can adenocarcinoma in situ of the uterine cervix be treated safely by conisation in combination with endocervical curettage? (25556275)
2014
28
Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. (24472852)
2014
29
Management of Adenocarcinoma In Situ of the Uterine Cervix: A Comparison of Loop Electrosurgical Excision Procedure and Cold Knife Conization. (25089550)
2014
30
Genomic alterations in pulmonary adenocarcinoma in situ in an adolescent patient. (24678688)
2014
31
Pathogenesis of combined high-grade squamous intraepithelial lesion and adenocarcinoma in situ of the uterine cervix: human papillomavirus genotype and methylation status and immunohistochemical study. (25612672)
2014
32
A report of adenocarcinoma in situ and congenital pulmonary airway malformation in a three-day-old infant with a review of the literature. (25341604)
2014
33
Clinical outcomes of patients with adenocarcinoma in situ of the cervix treated by conization. (25556268)
2014
34
Value of endocervical margin and high-risk human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and microinvasive carcinoma of the uterine cervix. (25284039)
2014
35
Adenocarcinoma in situ of the uterine cervix-a systematic review. (25238167)
2014
36
Early lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma. (24811831)
2014
37
A Case of HPV-negative Intestinal-type Endocervical Adenocarcinoma In Situ With Coexisting Multifocal Intestinal and Gastric Metaplasia. (24418863)
2014
38
Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section CT scan. (24351509)
2013
39
Long-term follow-up results from women with cervical adenocarcinoma in situ treated by conization: an experience from a large academic women's hospital. (23903202)
2013
40
Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ. (23946807)
2013
41
Conization using the Shimodaira-Taniguchi procedure for adenocarcinoma in situ of the uterine cervix. (23395556)
2013
42
Potential effects of updated pap test screening guidelines and adenocarcinoma in situ of the cervix. (23635675)
2013
43
Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. (23541795)
2013
44
Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. (23591077)
2013
45
PAX8 and PAX2 expression in endocervical adenocarcinoma in situ and high-grade squamous dysplasia. (23202787)
2013
46
Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women. (23552379)
2013
47
The value of CT attenuation in distinguishing atypical adenomatous hyperplasia from adenocarcinoma in situ. (24229623)
2013
48
Conization using the Shimodaira-Taniguchi procedure for adenocarcinoma in situ of the uterine cervix. (23790263)
2013
49
A case of synchronous bilateral lung cancers: EML4-ALK positive adenocarcinoma in the right lung and adenocarcinoma in situ (the former bronchioloalveolar carcinoma) in the left lung. (23617234)
2013
50
Cervical conization of adenocarcinoma in situ: a predicting model of residual disease. (24370689)
2013

Variations for Adenocarcinoma in Situ

About this section

Expression for genes affiliated with Adenocarcinoma in Situ

About this section
Search GEO for disease gene expression data for Adenocarcinoma in Situ.

Pathways for genes affiliated with Adenocarcinoma in Situ

About this section

GO Terms for genes affiliated with Adenocarcinoma in Situ

About this section

Cellular components related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein complexGO:00432348.7CDKN1A, CDX2, PAX2, TOP2A
2nucleolusGO:00057308.1CDKN1A, CDKN2A, MCM2, PAX2, TOP2A, WT1

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 32)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of cellular senescenceGO:200077410.7CDKN2A, KRAS
2mesenchymal to epithelial transition involved in metanephros morphogenesisGO:000333710.5PAX2, PAX8
3mesonephros developmentGO:000182310.5PAX2, PAX8
4metanephric distal convoluted tubule developmentGO:007222110.5PAX2, PAX8
5metanephric nephron tubule formationGO:007228910.5PAX2, PAX8
6negative regulation of apoptotic process involved in metanephric collecting duct developmentGO:190021510.5PAX2, PAX8
7negative regulation of apoptotic process involved in metanephric nephron tubule developmentGO:190021810.5PAX2, PAX8
8negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesisGO:007230510.5PAX2, PAX8
9negative regulation of mesenchymal cell apoptotic process involved in metanephros developmentGO:190021210.5PAX2, PAX8
10positive regulation of branching involved in ureteric bud morphogenesisGO:009019010.5PAX2, PAX8
11positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesisGO:007210810.5PAX2, PAX8
12positive regulation of metanephric DCT cell differentiationGO:200059410.5PAX2, PAX8
13mesenchymal to epithelial transitionGO:006023110.4PAX2, WT1
14metanephric mesenchyme developmentGO:007207510.4PAX2, WT1
15cellular response to gonadotropin stimulusGO:007137110.4PAX8, WT1
16metanephric S-shaped body morphogenesisGO:007228410.4PAX8, WT1
17cellular senescenceGO:009039810.3CDKN1A, CDKN2A
18negative regulation of cyclin-dependent protein serine/threonine kinase activityGO:004573610.3CDKN1A, CDKN2A
19negative regulation of phosphorylationGO:004232610.3CDKN1A, CDKN2A
20pronephric field specificationGO:003900310.3PAX2, PAX8
21pronephros developmentGO:004879310.3PAX2, PAX8
22regulation of metanephric nephron tubule epithelial cell differentiationGO:007230710.1PAX2, PAX8
23cochlea developmentGO:009010210.1MCM2, PAX2
24branching involved in ureteric bud morphogenesisGO:000165810.0PAX2, PAX8, WT1
25metanephric epithelium developmentGO:007220710.0PAX2, PAX8, WT1
26replicative senescenceGO:00903999.9CDKN1A, CDKN2A
27negative regulation of cell growthGO:00303089.9CDKN1A, CDKN2A, WT1
28urogenital system developmentGO:00016559.8PAX2, PAX8
29Ras protein signal transductionGO:00072659.7CDKN1A, CDKN2A, KRAS
30G1/S transition of mitotic cell cycleGO:00000829.5CDKN1A, CDKN2A, MCM2
31positive regulation of transcription, DNA-templatedGO:00458939.3CDKN2A, CDX2, PAX2, PAX8, WT1
32positive regulation of transcription from RNA polymerase II promoterGO:00459449.2CDKN2A, PAX2, PAX8, TOP2A, WT1

Molecular functions related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein serine/threonine kinase inhibitor activityGO:000486110.3CDKN1A, CDKN2A
2DNA bindingGO:00036777.4CDKN2A, CDX2, MCM2, PAX2, PAX8, TOP2A

Sources for Adenocarcinoma in Situ

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet